Reducing the risk of transfusion-transmitted cytomegalovirus infection: A systematic review and meta-analysis

Transfusion

Volumn 56, Issue 6, 2016, Pages 1569-1580

  Mainou, Maria ^a   Alahdab, Fares ^a   Tobian, Aaron A R ^b   Asi, Noor ^a   Mohammed, Khaled ^a   Murad, M Hassan ^a   Grossman, Brenda J ^c  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD COMPONENT; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HEMATOLOGICAL PROCEDURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; LEUKOCYTE; LEUKOREDUCTION; META ANALYSIS; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRANSFUSION TRANSMITTED CYTOMEGALOVIRUS INFECTION; VERY LOW BIRTH WEIGHT; VIRUS TRANSMISSION; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; FEMALE; LEUKAPHERESIS; MALE; PREGNANCY; PROCEDURES; RISK; TRANSMISSION;

BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MALE; PREGNANCY; RISK; TRANSFUSION REACTION;

EID: 84974604488     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13478     Document Type: Article

References (21)

1. Cannon MJ, Schmid DS, Hyde TB., Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010; 20: 202-13.
2. Tegtmeier GE., Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med 1989; 113: 236-45.
3. Hillyer CD, Emmens RK, Zago-Novaretti M, et al., Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion 1994; 34: 929-34.
4. Bowden R, Slichter SJ, Sayers M, et al., A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
5. Lieberman L, Devine DV, Reesink HW, et al., Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: standards of care. Vox Sang 2014; 107: 276-311.
6. Moher D, Liberati A, Tetzlaff J, et al., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
7. Eisenfeld L, Silver H, McLaughlin J, et al., Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32: 205-9.
8. Murphy MF, Grint PC, Hardiman AE, et al., Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. Br J Haematol 1988; 70: 253-4.
9. Nichols W, Price TH, Gooley T, et al., Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-200.
10. Pamphilon D, Foot A, Adeodu A, et al., Prophylaxis and prevention of CMV infection in BM allograft recipients: leukodepleted platelets are equivalent to those form CMV-seronegative donors. Bone Marrow Transplant 1999; 23: 566.
11. Ljungman P, Larsson K, Kumlien G, et al., Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 2002; 34: 347-50.
12. Blumberg N, Zhao H, Wang H, et al., The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47: 573-81.
13. Vamvakas EC., Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results? Vox Sang 2007; 93: 196-207.
14. Ohto H, Ujiie N, Hirai K., Lack of difference in cytomegalovirus transmission via the transfusion of filtered-irradiated and nonfiltered-irradiated blood to newborn infants in an endemic area. Transfusion 1999; 39: 201-5.
15. Xu D, Yonetani M, Uetani Y, et al., Acquired cytomegalovirus infection and blood transfusion in preterm infants. Acta Paediatr Jpn 1995; 37: 444-9.
16. Gilbert GL, Hayes K, Hudson IL, et al., Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1989; 1: 1228-31.
17. Bowden R, Slichter SJ, Sayers MH, et al., Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-50.
18. Josephson CD, Caliendo AM, Easley KA, et al., Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr 2014; 168: 1054-62.
19. Kekre N, Tokessy M, Mallick R, et al., Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 2013; 19: 1719-24.
20. Vamvakas E., Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? a review of the literature and meta-analysis. Transfus Med Rev 2005; 19: 181-99.
21. Hébert PC, Barrington KJ, Shapiro SH., Effectiveness of WBC reduction in neonates: what is the evidence of benefit? Transfusion 2002; 42: 159-65.